Clinical management and suggested treatment for COVID-19 in the Indian sub-continent: A comparative study

Abstract

SARS-CoV-2 is a dangerous virus which first emerged in China in December 2019. Till now, it has affected more than 4215,497 people in 212 countries and territories. No drug or vaccine is currently recommended, but scientists and researchers are trying their best to identify potential medications and clinical management practices for this virus. The aim of this paper is to find and compare clinical management practices and suggest potential treatment options for COVID-19 in highly infected countries of the Indian sub-continent (India, Bangladesh and Pakistan). Necessary information has been collected from various clinical management guidelines for COVID-19, available at the health ministry websites of India, Bangladesh and Pakistan. Although clinical management practices vary from country to country, all of these countries utilise mechanical ventilation. Moreover, some potential drugs have been suggested by all countries that may be utilised for treatment but did not recommend any of the medications yet because all of them are under evaluation in various clinical trials. Hydroxychloroquine has been suggested by all of these countries but in different situations. All countries are trying their best to follow their government guidelines. In addition, it has been found that the recovery rate of patients from Bangladesh, India and Pakistan is 18.08%, 30.76% and 26.58%, respectively. Although all the suggested treatment protocols have potentiality against COVID-19, they can only be recommended in the treatment procedure after necessary experiments and investigations.